CompletedNCT03408873
Adherence Support and Long-Acting Aripiprazole for People With Bipolarity
About this title
CAE Plus LAI in Individuals With Bipolar Disorder at Risk for Treatment Non-adherence (BD-CAEL)
Read the official source — NCT03408873Medication studyAges 18+United States
Understand this study
Who was this study for?
This study was for people with bipolarity. Listed age limits: from 18 years. Other eligibility criteria applied.
- Listed locations
- ClevelandSee all locations and recruitment
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
Study information
Study start dateStarted: April 1, 2018
- Recruitment status
- Completed
- Enrollment listed in the registry
- 30
- Sponsor
- Martha Sajatovic
- Sponsor type
- Unknown or unclear
- Study type
- Behavioral
- Intervention type
- Behavioural, Drug
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
- Locations
- United States
- Age range
- Over 18 Years
- Official registry ID
- NCT03408873
- Official title
Show the full official title
Enhancing Adherence and Outcomes in Bipolar Disorder With Abilify Maintena + a Targeted Behavioral Approach to Promote Sustained Adherence and Behavioral Change
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Cleveland
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Martha Sajatovic.
Did this study involve medication?
Yes. The study involved medication, including Abilify Maintena.
Who was this study for?
This study was for people with bipolarity. Listed age limits: from 18 years. Other eligibility criteria applied.
